Niagen Bioscience, Inc.
Close on Oct 19, 2026
- Market cap
- $206.26M
- P/E (TTM)
- 13.9
- Dividend yield
- –
Earnings
Next report expected Nov 3, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 4, 2026 | During market hours | $29.80M | $0.01 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 6, 2026 | During market hours | $31.50M | $0.07 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 4, 2026 | During market hours | $33.80M | $0.05 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 4, 2025 | During market hours | $34.00M | $0.05 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | During market hours | $31.10M | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 7, 2025 | During market hours | $30.50M | $0.06 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 4, 2025 | During market hours | $29.10M | $0.09 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 31, 2024 | During market hours | $25.60M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 7, 2024 | During market hours | $22.70M | $0.00 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 8, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 6, 2024 | During market hours | – | – | – |
Company guidance
Outlook given with results on Aug 4, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| e-commerce business | full year 2026 | 10% to 15% growth | Maintained |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Niagen Bioscience filed with the SEC
Niagen Bioscience, Inc. Reports Second Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Earnings Presentation Second Quarter 2026 Nasdaq: NAGE | August 4, 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Niagen Bioscience, Inc. Earnings Presentation First Quarter 2026 Nasdaq: NAGE | May 6, 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Niagen Bioscience Increases Share Repurchase Program to $20 Million
Other events · EX-99.1 to Form 8-K
Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Niagen Bioscience, Inc. Earnings Presentation Fourth Quarter and Full Year 2025 Nasdaq: NAGE | March 4, 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Niagen Bioscience to Streamline and Focus its Operations with the Sale of ChromaDex Reference Standards Business to LGC in All-Cash Transaction
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Niagen Bioscience Acquires Core Nicotinamide Riboside (NR) Patent Portfolio from Queen’s University Belfast
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Niagen Bioscience Announces $10 Million Share Repurchase Program
Other events · EX-99.1 to Form 8-K
Niagen Bioscience, Inc. Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Niagen Bioscience, Inc. Earnings Presentation Third Quarter 2025 Nasdaq: NAGE | November 4, 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Niagen Bioscience Increases Full Year 2025 Net Sales Outlook to 25% to 30% Year-Over-Year Growth
Regulation FD disclosure · EX-99.1 to Form 8-K
Niagen Bioscience, Inc. Reports Second Quarter 2025 Financial Results and Increases Full Year Outlook
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Niagen Bioscience, Inc. Earnings Presentation Second Quarter 2025 Nasdaq: NAGE | August 6, 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Niagen Bioscience, Inc. Earnings Presentation First Quarter 2025 Nasdaq: NAGE | May 7, 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ChromaDex Evolves into Niagen Bioscience, Marking a New Era of Uncovering the Potential of NAD+ with Precision Science
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2024 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
ChromaDex Earnings Conference Call Fourth Quarter 2024 Nasdaq: CDXC | March 4, 2025
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ChromaDex Corporation Reports Third Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
ChromaDex Earnings Presentation Third Quarter 2024 Rob Fried Chief Executive Officer Ozan Pamir Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | October 31, 2024
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ChromaDex Corporation Reports Second Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
ChromaDex Earnings Presentation Second Quarter 2024 Rob Fried Chief Executive Officer James Lee Interim Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | August 7, 2024
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ChromaDex Corporation Reports First Quarter 2024 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
ChromaDex Earnings Conference Call First Quarter 2024 Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | May 8, 2024
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
ChromaDex Earnings Conference Call Fourth Quarter 2023 Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | March 6, 2024
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ChromaDex Corporation Reports Third Quarter 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
ChromaDex Earnings Conference Call Third Quarter 2023 Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | November 8, 2023
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ChromaDex Corporation Reports Second Quarter 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
ChromaDex Earnings Conference Call Second Quarter 2023 Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | August 9, 2023
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ChromaDex Corporation Reports First Quarter 2023 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
ChromaDex Earnings Conference Call First Quarter 2023 Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | May 10, 2023
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
ChromaDex Earnings Conference Call Fourth Quarter 2022 Rob Fried Chief Executive Officer Brianna Gerber Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | March 8, 2023
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ChromaDex Corporation Reports Third Quarter 2022 Financial Results
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
ChromaDex Earnings Conference Call Third Quarter 2022 Rob Fried Chief Executive Officer Brianna Gerber SVP, Finance / Interim Chief Financial Officer Nasdaq: CDXC | November 2022
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
ChromaDex and Nestl é Health Science Announce New Niagen ® Commercial Supply Agreement and $5 Million Investment
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
ChromaDex Corporation Reports Second Quarter 2022 Financial Results
Results of operations · Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K